DLX6 and neoplasm: For instance, downregulated hsa_circ_0005379 facilitates the proliferation and metastasis of OSCC cells by regulating the EGFR pathway.96 The overexpression of distal-less homeobox 6 (DLX6) enhances proliferation and inhibits apoptosis in OSCC cells through the EGFR-CCND1 axis.97 Upregulated bone marrow stromal cell antigen 2 (BST2) promotes tumor growth and confers gefitinib resistance in OSCC patients via activating the EGFR pathway.98